Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Tofacitinib is an oral immunosuppressant approved for the treatment of rheumatoid arthritis (RA) and is currently undergoing investigation (Phase III trials) for treating chronic plaque psoriasis. Tofacitinib inhibits Janus kinases (JAKs), which are essential for the signaling of multiple inflammatory pathways and have been implicated in the pathogenesis of RA and psoriasis. The efficacy and safety of tofacitinib in the treatment of RA and psoriasis have been demonstrated in Phase III trials. Across all studies, the efficacy of tofacitinib in alleviating symptoms of RA and psoriasis were superior to placebo. Moreover, treatment was generally well-tolerated, with the most frequently reported adverse events, for both RA and psoriasis, being nasopharyngitis and upper respiratory tract infection. As such, tofacitinib proves to be an effective therapeutic option for RA and a promising new therapy for psoriasis.
University of Toronto Department of Medicine, Toronto, ON, Canada; Mediprobe Research Inc., London, ON, Canada.
A K
AK
Gupta
Mediprobe Research Inc., London, ON, Canada.
M
M
Cernea
University of Toronto Department of Medicine, Toronto, ON, Canada; Lynde Institute for Dermatology, Markham, ON, Canada.
C W
CW
Lynde
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D053616:Janus Kinase 3 / Q000037:antagonists & inhibitors*; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib; D053616:Janus Kinase 3